Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Study type
- Clinical guideline
- Study name
- ESMO Lymphomas 2025
- Design
- Clinical Practice Guideline from the ESMO Guidelines Committee
- Source
- Annals of Oncology · 2025
In plain words
This article is the European Society for Medical Oncology (ESMO) clinical guideline for doctors and explains how lymphomas (cancers of the lymphatic system) are diagnosed, treated and followed up. To make decisions about treatment, your test results and the exact type of lymphoma should be discussed with your treating doctor.
Study population
The PubMed record of this article has no abstract, so the target population and details of the guideline development method are not available. This section should be completed from the full text of the paper.
Endpoints
There is no abstract in the PubMed record. The title of the paper indicates that the guideline covers three areas: diagnosis, treatment and follow-up of lymphomas. Details should be extracted from the full text of the paper.
Safety and side effects
The available record gives no information on treatment-related adverse effects.
Clinical significance and place in guidelines
This article is the 2025 ESMO clinical guideline for the diagnosis, treatment and follow-up of lymphomas. The PubMed record has no abstract or specific recommendations, so its exact impact on clinical practice and the levels of evidence of the recommendations must be checked and confirmed from the full text of the guideline.
Limitations
There is no abstract in the PubMed record, and the recommendations, levels of evidence and details of treatment regimens were not available. The full text of the paper must be reviewed to record the recommendations.
This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.